62679-61-2

Usage

Uses

Used in Coordination Chemistry:
4,4-Difluoro-1-phenyl-1,3-butanedione is used as a ligand for the formation of metal complexes, which are essential in coordination chemistry. The metal complexes formed with DPBD include:
Eu(DPBD)3·H2O: A europium complex with a water molecule coordinated to the metal center.
Eu(DPBD)3·biq (biq = 2,2-biquinoline): A europium complex with biquinolines as ancillary ligands.
Eu(DPBD)3·phen (phen = 1,10-phenanthroline): A europium complex with phenanthroline ligands, which can enhance the luminescent properties of the complex.
Eu(DPBD)3·neo (neo = neocuproine): A europium complex with neocuproine ligands, which can improve the stability and solubility of the complex.
Eu(DPBD)3·bipy (bipy = 2,2-bipyridyl): A europium complex with bipyridyl ligands, which can modulate the electronic properties of the complex.
Gd(DPBD)3·(H2O)2: A gadolinium complex with two water molecules coordinated to the metal center, which can be used in magnetic resonance imaging (MRI) contrast agents.
These metal complexes have potential applications in various fields, such as luminescent materials, catalysts, and medical imaging. The use of DPBD as a ligand allows for the fine-tuning of the properties of these metal complexes, making them suitable for specific applications.

InChI:InChI=1/C10H8F2O2/c11-10(12)9(14)6-8(13)7-4-2-1-3-5-7/h1-5,10H,6H2

Upstream product

• 433-53-4 difluoroacetic acid methyl ester 
• 98-86-2 acetophenone 
• 454-31-9 ethyl difluoroacetate 

Downstream Products

• 343629-25-4 5-methylsulfonyl-2-[5-phenyl-3-difluoromethyl-1H-pyrazol-1-yl]pyridine 
• 21048-30-6 ¹⁸O-benzoic acid 
• 929606-77-9 C₁₆H₁₁BrF₂N₂ 
• 929606-92-8 C₁₆H₁₁BrF₂N₂ 
• 929606-90-6 C₁₆H₁₃F₂N₃O₂S 
• 78407-59-7 tris(1,1-difluoro-(4-phenyl)butane-2,4-dionato)aluminum(III) 
• 572915-12-9 2-(1-adamantyl)-4,4-difluoro-1-phenylbutane-1,3-dione 

Relevant academic research and scientific papers

Synthesis, Photoluminescence Behavior of Green Light Emitting Tb(III) Complexes and Mechanistic Investigation of Energy Transfer Process

A series of five new terbium(III) ion complexes with 4,4-difluoro-1-phenylbutane-1,3-dione (HDPBD) and anciliary ligands was synthesized. The composition and properties of complexes were analyzed by elemental analysis, IR, NMR, powder X-ray diffaraction,

Synthesis, photoluminescent features and intramolecular energy transfer mechanism of europium (III) complexes with fluorinate β-diketone ligand and auxiliary ligands

Abstract A series of novel luminescent europium (III) complexes based on fluorinated β-diketone ligand 4,4-difluoro-1-phenyl-1,3-butanedione (DPBD) and auxiliary ligands 2,2-biquinoline (biq) or 1,10-phenanthroline (phen) or neocuproine (neo) or 2,2-bipyr

Discovery of a potent, selective and orally active canine COX-2 inhibitor, 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl-pyridine

Structure-activity relationship (SAR) studies of 2-[3-di(and tri)fluoromethyl-5-arylpyrazol-1-yl]-5-methanesulfonylpyridine derivatives for canine COX enzymes are described. This led to the identification of 12a as a lead candidate for further progression. The in vitro and in vivo activity of 12a for the canine COX-2 enzyme as well as its in vivo efficacy and pharmacokinetic properties in dog are highlighted.

Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)- 3(trifluoromethyl)-1h-pyrazol-1-yl]benzenesulfonamide (sc-58635, celecoxib)

A series of sulfonamide-containing 1,5-diarylpyrazole derivatives were prepared and evaluated for their ability to block cyclooxygenase-2 (COX-2) in vitro and in vivo. Extensive structure-activity relationship (SAR) work was carried out within this series, and a number of potent and selective inhibitors of COX-2 were identified. Since an early structural lead (1f, SC- 236) exhibited an unacceptably long plasma half-life, a number of pyrazole analogs containing potential metabolic sites were evaluated further in vivo in an effort to identify compounds with acceptable pharmacokinetic profiles. This work led to the identification of 1i (4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-y1]benzenesulfonamide, SC-58635, celecoxib), which is currently in phase III clinical trials for the treatment of rheumatoid arthritis and osteoarthritis.